Peptide study claims: distinguish a registry entry from a result

Write the claim narrowly

Copy the claim you want to evaluate into a private research note and identify what it asserts: an effect in cells, an animal result, a change in a measured human outcome or an approved use of a particular product. Those are different propositions. Record the named substance, studied formulation and source before deciding whether the cited evidence addresses the claim.

This guide is research literacy, not a recommendation to use a peptide or join a study. It does not assess a particular treatment, rank suppliers or interpret an individual's medical condition. It describes a way to keep evidence categories separate using US FDA and ClinicalTrials.gov educational sources reviewed September 14, 2026.

Identify the study stage and question

FDA distinguishes preclinical work from clinical research in people and describes how clinical protocols define such matters as participants, duration, control groups and assessments. A laboratory observation cannot simply be relabeled as a demonstrated human benefit. Read the study's actual population and question before interpreting a promotional summary. [1]

Make separate fields for planned enrollment and analyzed participants, the comparison group, the outcome measured and the follow-up period. If a paper or registry record does not provide a field, mark it unavailable. A phase label is a starting point for reading the study; it is not a complete assessment of its methods or results.

Keep registration, completion and results apart

ClinicalTrials.gov cautions that listing a study does not mean the US government has approved its safety or scientific merit, and that not all listed studies are government funded or overseen. A listing therefore should not be presented as an endorsement of a substance or seller. [2]

Check whether the source is a study registration, a protocol, posted results, a preprint or a published report. Record the version and date. A completed recruitment status does not tell you the outcome, and a planned outcome field is not a result. Follow the record to the actual results when available; leave the result unresolved when it is not.

An invented claim-to-evidence mismatch

Suppose a fictional seller says 'shown to improve recovery in adults' and links to a registry entry whose record only describes a planned human study. The worksheet should say that the source establishes a planned question and population, while the claimed benefit remains unsupported by that record. Do not rewrite the entry as a negative result either.

Now suppose an invented paper reports a change in a laboratory marker in a small group, while the headline promises an improvement in everyday function. Record the measured marker and the headline's different outcome side by side. The gap is the finding of this exercise. It is not an estimate of how a real patient would respond.

Write a bounded conclusion

A useful conclusion names the source and its limits: 'This record describes a planned study; no results were available in the reviewed source on the access date.' Where results are available, report the population, measured outcome and comparison without extending them to different products, formulations or uses.

Use the worksheet to list unresolved questions for further reading or discussion with an appropriately qualified professional. Do not convert the number of citations into a quality score or treat a seller's product as equivalent to the material studied. FDA's development overview separates research from the regulatory review that decides whether to approve a product. [3]

Retain both the original claim and your dated evidence note. If the registry or publication later changes, append the new finding rather than silently changing what the earlier record showed. The result is a traceable reading record, not a clinical recommendation, regulatory determination or guarantee of safety.